Nordea Investment Management Trims Amgen Stake

Institutional investor sells over 273,000 shares of the biotech giant

Mar. 22, 2026 at 10:07am

Got story updates? Submit your updates here. ›

Nordea Investment Management AB, an institutional investor, has reduced its position in Amgen Inc. (NASDAQ:AMGN) by 9.5% in the fourth quarter, according to a recent SEC filing. The firm sold 273,268 shares of the medical research company's stock, leaving it with 2,601,135 shares, or approximately 0.48% ownership of Amgen.

Why it matters

Amgen is one of the world's largest biotechnology companies, developing and manufacturing innovative human therapeutics. Institutional investors closely monitor and adjust their positions in major biotech firms like Amgen, as changes in ownership can signal shifts in market sentiment or the company's performance.

The details

According to the filing, Nordea Investment Management AB now owns 2,601,135 shares of Amgen, worth approximately $851,924,000 at the end of the reporting period. The firm's position in Amgen comprises 0.7% of its total investment portfolio, making it the 26th largest holding.

  • Nordea Investment Management AB reduced its Amgen stake in the fourth quarter of 2025.

The players

Nordea Investment Management AB

A major institutional investor that manages over $500 billion in assets globally.

Amgen Inc.

A leading global biotechnology company that discovers, develops, manufactures and delivers innovative human therapeutics.

Got photos? Submit your photos here. ›

The takeaway

This reduction in Nordea's Amgen stake, while relatively small, could signal a broader shift in investor sentiment around the biotech sector or Amgen's specific outlook. Institutional investors closely monitor and adjust their positions in major biotech firms, so changes in ownership can provide insights into the market's views on a company's performance and future prospects.